Welcome!

News Feed Item

Robert A. Essner, former Chairman and Chief Executive of Wyeth, named Executive Chairman of Elucida Oncology, Inc.

NEW YORK, NY--(Marketwired - April 25, 2018) - ELUCIDA ONCOLOGY, INC®, a biotechnology company focused on developing and commercializing a first-in-class, ultra-small nanoparticle platform technology for the diagnosis and treatment of cancer, announced today that it has appointed Robert A. Essner as its Executive Chairman. Mr. Essner was Chairman and Chief Executive Officer for Wyeth, acquired by Pfizer in 2009. In his 32 years in the pharmaceutical industry Mr. Essner has held numerous high-level leadership roles that included Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA). He is Chairman of the not-for-profit Children's Health Fund, and a Trustee of Mote Marine Laboratory, as well as Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in Healthcare Management.

Mr. Essner is also an Operating Executive for The Carlyle Group, and a member of the Board of Directors for Amicus Therapeutics and has just completed a 16-year term on the Board of Directors for MassMutual.

Isaac Blech, Vice Chairman of the Board of Directors of Elucida Oncology, commented, "All of us at Elucida are extremely pleased to bring an executive of Bob Essner's stature into the company to help Elucida achieve its goal of becoming a leading precision medicine oncology company."

"I welcome Bob to Elucida and look forward to his considerable experience being applied to the Elucida C-Dot platform as we bring to market first-in-class diagnostic and therapeutic products to positively impact the lives of cancer patients," said Edward Rosen, Elucida's President and Chief Executive Officer. "Bob Essner is a pivotal leader in the pharmaceutical industry. We are delighted to have Bob join us as Executive Chairman."

"I am very excited to be part of what is being built at Elucida Oncology," stated Mr. Essner. "Advancing innovation to change and save lives has been the core of my career for over 30 years. At Elucida, we have a remarkable first-in-class particle platform. This is a rare opportunity to make a compelling improvement to the world of precision oncology, in diagnostic and therapeutic applications. I am proud to be part of this effort and this team."

About Elucida Oncology

Elucida Oncology, Inc., is a privately held, clinical-stage biotechnology company focused on developing and commercializing a first-in-class ultrasmall nanoparticle platform for the diagnosis, visualization and treatment of primary solid tumor and metastatic cancers. The novel Target or Clear™ characteristic of the C-Dot product platform is demonstrating the combination of advanced cancer cell targeting combined with the potential safety advance afforded by bulk clearance through the renal system.

For more information on Elucida Oncology, Inc., please visit www.elucidaoncology.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Elucida's product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Elucida does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

The Elucida Oncology name and logo are registered trademarks of Elucida Oncology Incorporated. Target or Clear is a trademark of Elucida Oncology Incorporated.

Elucida Oncology, Inc.
Edward Rosen
President and Chief Executive Officer
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Jo Peterson is VP of Cloud Services for Clarify360, a boutique sourcing and benchmarking consultancy focused on transforming technology into business advantage. Clarify360 provides custom, end-to-end solutions from a portfolio of more than 170 suppliers globally. As an engineer, Jo sources net new technology footprints, and is an expert at optimizing and benchmarking existing environments focusing on Cloud Enablement and Optimization. She and her team work with clients on Cloud Discovery, Cloud ...
This is going to be a live demo on a production ready CICD pipeline which automate the deployment of application onto AWS ECS and Fargate. The same pipeline will automate deployment into various environment such as Test, UAT, and Prod. The pipeline will go through various stages such as source, build, test, approval, UAT stage, Prod stage. The demo will utilize only AWS services including AWS CodeCommit, Codebuild, code pipeline, Elastic container service (ECS), ECR, and Fargate.
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
If a machine can invent, does this mean the end of the patent system as we know it? The patent system, both in the US and Europe, allows companies to protect their inventions and helps foster innovation. However, Artificial Intelligence (AI) could be set to disrupt the patent system as we know it. This talk will examine how AI may change the patent landscape in the years to come. Furthermore, ways in which companies can best protect their AI related inventions will be examined from both a US and...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Behera Rasananda is a technologist, a leader, a key note speaker has more than 20 years experience in across Government, Financial, Heath Care and Insurance Verticals. Mr. Behera has vast experience in Enterprise Cloud and Big Data solutions and Enterprise Architecture. Currently he works closely for Government Solutions on Enterprise Cloud for Federal Government Agency. Scientist Behera managed and partner with clients to make complete end to end solution and Migration to cloud both private sec...
Everyone wants the rainbow - reduced IT costs, scalability, continuity, flexibility, manageability, and innovation. But in order to get to that collaboration rainbow, you need the cloud! In this presentation, we'll cover three areas: First - the rainbow of benefits from cloud collaboration. There are many different reasons why more and more companies and institutions are moving to the cloud. Benefits include: cost savings (reducing on-prem infrastructure, reducing data center foot print, r...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
Excitement and interest in APIs has skyrocketed in recent years. However, if you ask a room full of IT professionals "What is an API", you will get a wide array of answers. There exists a wide knowledge gap between API experts and those that have a general idea of what they are, but are unsure of what they have been for in the past, what they look like now, and how they can be used to expand your business in the future. In this session John will cover what the history of APIs, what an API looks ...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...